Analogue-based Drug Discovery II
ISBN: 9783527325498 | 3527325492
Edition: 1stFormat: Hardcover
Publisher: Wiley-VCH
Pub. Date: 8/30/2010
Why Rent from Knetbooks?
Because Knetbooks knows college students. Our rental program is designed to save you time and money. Whether you need a textbook for a semester, quarter or even a summer session, we have an option for you. Simply select a rental period, enter your information and your book will be on its way!
Top 5 reasons to order all your textbooks from Knetbooks:
- We have the lowest prices on thousands of popular textbooks
- Free shipping both ways on ALL orders
- Most orders ship within 48 hours
- Need your book longer than expected? Extending your rental is simple
- Our customer support team is always here to help
Born out of a project of the IUPAC's committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by ten new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes constitute the first systematic approach to ... MORE
| General Aspects | |
| Optimizing Drug Therapy by Analogues | |
| Standalone Drugs | |
| Application of Molecular Modeling in Analogue-Based Drug Discovery | |
| Issues for the Patenting of Analogues | |
| Analogue Classes | |
| Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes | |
| Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction | |
| Ri... MORE | |
| Monoterpenoid Indole Alkaloids, CNS Anticancer Drugs | |
| Anthracyclines, Optimizing Anticancer Analogues | |
| Paclitaxel and Epothilone Analogues, Anticancer Drugs | |
| Selective Serotonin Reuptake Inhibitors for the Treatment of Depression | |
| Muscarinic Receptor Antagonists in the Treatment of COPD | |
| beta-Adrenoceptor Agonists and Asthma | |
| Case Histories | |
| Liraglutide, a GLP-1 Analogue to Treat Diabetes | |
| Eplerenone: Selective Aldosterone Antagonist | |
| Clevudine, to Treat Hepatitis B Viral Infection | |
| Rilpivirine, a Non-nucleoside Reverse Transcriptase Inhibitor to Treat HIV-1 | |
| Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-drug Resistant HIV | |
| Lapatinib, an Anticancer Kinase Inhibitor | |
| Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia | |
| Venlafaxine and Desvenlafaxine, Selective Norepinephrine and Serotonin | |
| Reuptake Inhibitors to Treat Major Depressive Disorder | |
| Table of Contents provided by Publisher. All Rights Reserved. |
J?nos Fischer is a Senior Research Scientist at Richter Plc., Budapest, Hungary. He received his MSc and PhD degrees in organic chemistry from the Eotvos University of Budapest under Professor A. Kucsman. Between 1976 and 1978, he was a Humboldt Fellow at the University of Bonn under Professor W. Steglich. He has worked at Richter Plc. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest is analogue based drug discovery. He is the author of some 100 patents and scientific publications. In 2004, he was elected as a Titular member of the Chemistry and Human Health Division of IUPAC. He received an honorary professorship at the Technical University of Budapest.
C. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co inventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is co inventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
C. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co inventors of the revolutionary drug, cimetidine (also known as Tagamet). In 1986, he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Professor Emeritus of Medicinal Chemistry. Professor Ganellin is co inventor of over 160 patents and has authored over 260 scientific publications. He was President of the Medicinal Chemistry Section of the IUPAC and is Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.
Please wait while this item is added to your cart...
